FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res Commun / Interventions for treatment of cutaneous melanoma in horses:...
Veterinary research communications2022; 47(2); 347-360; doi: 10.1007/s11259-022-10023-8

Interventions for treatment of cutaneous melanoma in horses: a structured literature review.

Abstract: Several therapies have been developed to treat equine cutaneous melanoma, but formal comparisons among different treatment options are currently unavailable. It was our intent to assess the efficacy of different treatment protocols and the quality of the studies based on the original published data, and summarize the knowledge concerning the outcome after equine cutaneous melanoma management. This structured review followed PRISMA procedure to search for treatment protocols on equine cutaneous melanoma published from 1960 until June 2021. Studies were assessed for the risk of bias. A descriptive analysis was performed, considering the disease control rate, the recurrence rate of the tumor, comorbidities, need for anesthesia, and horses' welfare. Twenty-three studies were included, from which the treatment outcomes of 173 horses were assessed. The homogeneity of the included trials was low. The percentages of each treatment arm achieving a partial response and curative effects accounted for 93.1% (surgical intervention), 90% (medication), and 39.4% (immunotherapies), respectively. A variable efficacy of different therapies of equine cutaneous melanoma was observed. Surgical intervention performed the best from the perspective of local antitumor effects alone. This literature review and descriptive analysis can serve as a source to assist in designing quality therapy research and can potentially aid in providing a clinical treatment reference for equine cutaneous melanoma.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Get Full Text
Publication Date: 2022-11-04 PubMed ID: 36329228PubMed Central: 6705183DOI: 10.1007/s11259-022-10023-8Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article summarizes a review of studies on different treatment methods for cutaneous melanoma in horses. The review evaluates the effectiveness of these treatments, their respective outcomes, and the quality of each study.

Summary of Methods

  • The researchers conducted a structured literature review following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) procedure.
  • They searched for studies on various treatment protocols for equine cutaneous melanoma published between 1960 and June 2021.
  • The team assessed each study for potential bias and performed a descriptive analysis to evaluate the effectiveness of the treatments.

Findings

  • Twenty-three studies met the criteria and were included in the review.
  • The outcomes of 173 horses from these studies were assessed, but there was found to be low homogeneity among the trials, meaning the studies’ designs, treatments, and outcomes varied widely.
  • The analysis considered multiple factors, such as disease control rate, recurrence of the tumor, associated health conditions (co-morbidities), need for anesthesia, and the overall welfare of the horses.

Treatment Outcomes: Comparison

  • On comparing the effects of different treatments, the review found that surgical interventions had the highest partial response rate at 93.1%.
  • Medication treatments followed closely, achieving a 90% rate.
  • Immunotherapies had the lowest rate at 39.4%.
  • This suggested variable efficacy among the different therapies, with surgical intervention performing best in terms of localized antitumor effects.

Implications

  • This literature review and descriptive analysis are useful for designing high-quality research into therapy options for equine cutaneous melanoma.
  • The results may also aid clinicians in selecting the most suitable treatment options for this condition in horses.

Cite This Article

APA
Yi Z, Gao Y, Yu F, Zhu Y, Liu H, Li J, Murua Escobar H. (2022). Interventions for treatment of cutaneous melanoma in horses: a structured literature review. Vet Res Commun, 47(2), 347-360. https://doi.org/10.1007/s11259-022-10023-8

Publication

Veterinary research communications
ISSN: 1573-7446
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 47
Issue: 2
Pages: 347-360

Researcher Affiliations

Yi, Ziwen
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agriculture University, No. 2 Yuanmingyuan West Road, 100094, Beijing, China.
Gao, Yu
  • University of Veterinary Medicine Hannover Foundation, Hannover, Germany.
Yu, Feng
  • College of Veterinary Medicine, China Agriculture University, Beijing, China.
Zhu, Yiping
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agriculture University, No. 2 Yuanmingyuan West Road, 100094, Beijing, China.
Liu, Haoqian
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agriculture University, No. 2 Yuanmingyuan West Road, 100094, Beijing, China.
Li, Jing
  • Equine Clinical Diagnostic Center, College of Veterinary Medicine, China Agriculture University, No. 2 Yuanmingyuan West Road, 100094, Beijing, China. jlivet@cau.edu.cn.
Murua Escobar, Hugo
  • Department of Hematology, Oncology and Palliative Medicine, Department of Medicine III, Rostock University Medical Center, Ernst Heydemann Street No. 6, 18057, Rostock, Germany. hugo.murua.escobar@med.uni-rostock.de.

MeSH Terms

  • Horses
  • Animals
  • Melanoma / therapy
  • Melanoma / veterinary
  • Skin Neoplasms / therapy
  • Skin Neoplasms / veterinary
  • Horse Diseases / therapy

Grant Funding

  • 1051-2221002 / The Talent Fund of China Agricultural University Veterinary Teaching Hospital (Beijing Zhongnongda Veterinary Hospital Co., Ltd.)

References

This article includes 71 references
  1. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius.. Biotechnol Bioeng 1969 Nov;11(6):1101-10.
    doi: 10.1002/bit.260110607pubmed: 5365804google scholar: lookup
  2. Billi T, Karadima V, Tyrnenopoulou P, Apostolopoulou EP, Brellou GD, Diakakis N. Surgical excision of a malignant metastatic melanoma located in a skeletal muscle of the lateral thorax of a horse.. Vet Med Sci 2021 Mar;7(2):297-302.
    doi: 10.1002/vms3.366pubmed: 32991055google scholar: lookup
  3. Bradley WM, Schilpp D, Khatibzadeh SM. Electronic brachytherapy used for the successful treatment of three different types of equine tumours. Equine Vet Educ 29:293–298.
    doi: 10.1111/eve.12420google scholar: lookup
  4. Brockley LK, Cooper MA, Bennett PF. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.. N Z Vet J 2013 Jan;61(1):25-31.
    doi: 10.1080/00480169.2012.699433pubmed: 22913610google scholar: lookup
  5. Brown EL, Angela DV, Cara AW. Treatment of metastatic equine melanoma with a plasmid DNA vaccine encoding Streptococcus Pyogenes EMM55 protein. J Equine Vet Sci 34:704–708.
    doi: 10.1016/j.jevs.2013.11.012google scholar: lookup
  6. Byron CR, DeWitt MR, Latouche EL, Davalos RV, Robertson JL. Treatment of Infiltrative Superficial Tumors in Awake Standing Horses Using Novel High-Frequency Pulsed Electrical Fields.. Front Vet Sci 2019;6:265.
    doi: 10.3389/fvets.2019.00265pubmed: 31475163pmc: 6705183google scholar: lookup
  7. Campagne C, Julé S, Bernex F, Estrada M, Aubin-Houzelstein G, Panthier JJ, Egidy G. RACK1, a clue to the diagnosis of cutaneous melanomas in horses.. BMC Vet Res 2012 Jun 29;8:95.
    doi: 10.1186/1746-6148-8-95pubmed: 22747534pmc: 3543212google scholar: lookup
  8. Curik I, Druml T, Seltenhammer M, Sundström E, Pielberg GR, Andersson L, Sölkner J. Complex inheritance of melanoma and pigmentation of coat and skin in Grey horses.. PLoS Genet 2013;9(2):e1003248.
    doi: 10.1371/journal.pgen.1003248pubmed: 23408897pmc: 3567150google scholar: lookup
  9. Druml T, Brem G, Horna M, Ricard A, Grilz-Seger G. DPF3, A Putative Candidate Gene For Melanoma Etiopathogenesis in Gray Horses.. J Equine Vet Sci 2022 Jan;108:103797.
    doi: 10.1016/j.jevs.2021.103797pubmed: 34801788google scholar: lookup
  10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).. Eur J Cancer 2009 Jan;45(2):228-47.
    doi: 10.1016/j.ejca.2008.10.026pubmed: 19097774google scholar: lookup
  11. Finocchiaro LM, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma.. Cancer Gene Ther 2008 Mar;15(3):165-72.
    doi: 10.1038/sj.cgt.7701096pubmed: 18219342google scholar: lookup
  12. Finocchiaro LM, Riveros MD, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse.. Vet Rec 2009 Feb 28;164(9):278-9.
    doi: 10.1136/vr.164.9.278pubmed: 19252217google scholar: lookup
  13. Foley GL, Valentine BA, Kincaid AL. Congenital and acquired melanocytomas (benign melanomas) in eighteen young horses.. Vet Pathol 1991 Sep;28(5):363-9.
    doi: 10.1177/030098589102800503pubmed: 1750161google scholar: lookup
  14. Fowles JS, Denton CL, Gustafson DL. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.. Vet Comp Oncol 2015 Sep;13(3):288-304.
    doi: 10.1111/vco.12044pubmed: 23745794google scholar: lookup
  15. Ganbaatar O, Konnai S, Okagawa T, Nojima Y, Maekawa N, Minato E, Kobayashi A, Ando R, Sasaki N, Miyakoshi D, Ichii O, Kato Y, Suzuki Y, Murata S, Ohashi K. PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.. PLoS One 2020;15(11):e0234218.
    doi: 10.1371/journal.pone.0234218pubmed: 33216754pmc: 7678989google scholar: lookup
  16. Gillette EL, Gillette SM. Principles of radiation therapy.. Semin Vet Med Surg Small Anim 1995 Aug;10(3):129-34.
    pubmed: 8532968
  17. Goetz TE, Ogilvie GK, Keegan KG, Johnson PJ. Cimetidine for treatment of melanomas in three horses.. J Am Vet Med Assoc 1990 Feb 1;196(3):449-52.
    pubmed: 2298676
  18. Goetz TE. Management of melanomas. .
  19. Groom LM, Sullins KE. Surgical excision of large melanocytic tumours in grey horses: 38 cases (2001–2013). Equine Vet Educ 30:438–443.
    doi: 10.1002/vms3.366google scholar: lookup
  20. Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, Moelling K. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses.. J Mol Med (Berl) 2001;78(12):692-702.
    doi: 10.1007/s001090000165pubmed: 11434722google scholar: lookup
  21. Hewes CA, Sullins KE. Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).. J Am Vet Med Assoc 2006 Nov 15;229(10):1617-22.
    doi: 10.2460/javma.229.10.1617pubmed: 17107319google scholar: lookup
  22. Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.. Nat Med 2021 Mar;27(3):515-525.
    doi: 10.1038/s41591-020-01206-4pubmed: 33479501pmc: 8273876google scholar: lookup
  23. Jeong H, Kwon Y. Topical chemotherapy using cisplatin for treatment of malignant melanoma in a grey horse. Pak Vet J 40:130–132.
    doi: 10.29261/pakvetj/2019.072google scholar: lookup
  24. Jiang L, Campagne C, Sundström E, Sousa P, Imran S, Seltenhammer M, Pielberg G, Olsson MJ, Egidy G, Andersson L, Golovko A. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.. BMC Cancer 2014 Nov 21;14:857.
    doi: 10.1186/1471-2407-14-857pubmed: 25413220pmc: 4254013google scholar: lookup
  25. Johnson PJ. Dermatologic tumors (excluding sarcoids). Vet Clin North Am Equine Pract 14:625–658, viii.
    doi: 10.1016/s0749-0739(17)30190-6google scholar: lookup
  26. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials.. BMJ 2001 Jul 7;323(7303):42-6.
    doi: 10.1136/bmj.323.7303.42pubmed: 11440947pmc: 1120670google scholar: lookup
  27. Khosla S, Kennedy L, Abdulaal Y. Cisplatin induced acute mesenteric ischaemia: A case report and review of the literature.. Int J Surg Case Rep 2017;41:347-351.
    doi: 10.1016/j.ijscr.2017.11.007pubmed: 29145109pmc: 5686456google scholar: lookup
  28. Laus F, Cerquetella M, Paggi E. Evaluation of cimetidine as a therapy for dermal melanomatosis in grey horse. Isr J Vet Med 65:48–52.
  29. Lembcke LM, Kania SA, Blackford JT. Development of immunologic assays to measure response in horses vaccinated with xenogeneic plasmid DNA encoding human tyrosinase. J Equine Vet Sci 32:607–615.
    doi: 10.1016/j.jevs.2012.02.011google scholar: lookup
  30. LeRoy BE, Knight MC, Eggleston R, Torres-Velez F, Harmon BG. Tail-base mass from a "horse of a different color".. Vet Clin Pathol 2005;34(1):69-71.
    doi: 10.1111/j.1939-165x.2005.tb00014.xpubmed: 15732023google scholar: lookup
  31. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.. BMJ 2009 Jul 21;339:b2700.
    doi: 10.1136/bmj.b2700pubmed: 19622552pmc: 2714672google scholar: lookup
  32. Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JM, Paschke R. In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and in vivo safety assessment of the compound NVX-207 in two horses.. Chem Biol Interact 2016 Feb 25;246:20-9.
    doi: 10.1016/j.cbi.2016.01.002pubmed: 26772157google scholar: lookup
  33. Logotheti S, Marquardt S, Richter C, Sophie Hain R, Murr N, Takan I, Pavlopoulou A, Pützer BM. Neural Networks Recapitulation by Cancer Cells Promotes Disease Progression: A Novel Role of p73 Isoforms in Cancer-Neuronal Crosstalk.. Cancers (Basel) 2020 Dec 16;12(12).
    doi: 10.3390/cancers12123789pubmed: 33339112pmc: 7765507google scholar: lookup
  34. MacGillivray KC, Sweeney RW, Del Piero F. Metastatic melanoma in horses.. J Vet Intern Med 2002 Jul-Aug;16(4):452-6.
    doi: 10.1111/j.1939-1676.2002.tb01264.xpubmed: 12141308google scholar: lookup
  35. MacKay RJ. Treatment Options for Melanoma of Gray Horses.. Vet Clin North Am Equine Pract 2019 Aug;35(2):311-325.
    doi: 10.1016/j.cveq.2019.04.003pubmed: 31279435google scholar: lookup
  36. Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.. BMC Vet Res 2015 May 14;11:107.
    doi: 10.1186/s12917-015-0414-9pubmed: 25967290pmc: 4429833google scholar: lookup
  37. McCauley CT, Hawkins JF, Adams SB, Fessler JF. Use of a carbon dioxide laser for surgical management of cutaneous masses in horses: 32 cases (1993-2000).. J Am Vet Med Assoc 2002 Apr 15;220(8):1192-7.
    doi: 10.2460/javma.2002.220.1192pubmed: 11990967google scholar: lookup
  38. Mcfadyean J. Equine melanomatosis. J Comp Pathol Ther 46:186–204.
  39. Moore JS, Shaw C, Shaw E. Melanoma in horses: current perspectives. Equine Vet Educ 25:144–151.
    doi: 10.1111/j.2042-3292.2011.00368.xgoogle scholar: lookup
  40. Müller J, Feige K, Wunderlin P, Hödl A, Meli ML, Seltenhammer M, Grest P, Nicolson L, Schelling C, Heinzerling LM. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses.. J Immunother 2011 Jan;34(1):58-64.
    doi: 10.1097/CJI.0b013e3181fe1997pubmed: 21150713google scholar: lookup
  41. Owen LN. TNM classification of tumours in domestic animals. .
  42. Page RL, Thrall DE. Clinical indications and applications of radiotherapy and hyperthermia in veterinary oncology.. Vet Clin North Am Small Anim Pract 1990 Jul;20(4):1075-92.
    doi: 10.1016/s0195-5616(90)50085-6pubmed: 2196731google scholar: lookup
  43. Ramos-Vara JA, Frank CB, DuSold D, Miller MA. Immunohistochemical expression of melanocytic antigen PNL2, Melan A, S100, and PGP 9.5 in equine melanocytic neoplasms.. Vet Pathol 2014 Jan;51(1):161-6.
    doi: 10.1177/0300985812471545pubmed: 23370093google scholar: lookup
  44. Rizk A, Mosbah E, Karrouf G, Abou Alsoud M. Surgical Management of Penile and Preputial Neoplasms in Equine with Special Reference to Partial Phallectomy.. J Vet Med 2013;2013:891413.
    doi: 10.1155/2013/891413pubmed: 26464915pmc: 4590862google scholar: lookup
  45. Robertson J. Lymphosarcoma and other rare skin tumors. .
  46. Rodríguez M, García-Barona V, Peña L. Grey horse melanotic condition: A pigmentary disorder. J Equine Vet Sci 17:677–681.
    doi: 10.1016/S0737-0806(97)80270-5google scholar: lookup
  47. Rowe EL, Sullins KE. Excision as treatment of dermal melanomatosis in horses: 11 cases (1994-2000).. J Am Vet Med Assoc 2004 Jul 1;225(1):94-6.
    doi: 10.2460/javma.2004.225.94pubmed: 15239480google scholar: lookup
  48. Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.. J Clin Oncol 2021 Aug 20;39(24):2656-2666.
    doi: 10.1200/jco.21.00612pubmed: 33979178pmc: 8376325google scholar: lookup
  49. Scacco L, Alfonso B, Antonio R. Adjuvant electrochemotherapy increases local control in a recurring equine anal melanoma. J Equine Vet Sci 33:637–639.
    doi: 10.1016/j.jevs.2012.09.006google scholar: lookup
  50. Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, Niebauer GW. Comparative histopathology of grey-horse-melanoma and human malignant melanoma.. Pigment Cell Res 2004 Dec;17(6):674-81.
    doi: 10.1111/j.1600-0749.2004.00192.xpubmed: 15541026google scholar: lookup
  51. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. Systemic Therapy for Melanoma: ASCO Guideline.. J Clin Oncol 2020 Nov 20;38(33):3947-3970.
    doi: 10.1200/jco.20.00198pubmed: 32228358google scholar: lookup
  52. Shrivastav S, Bonar RA, Stone KR, Paulson DF. An in vitro assay procedure to test chemotherapeutic drugs on cells from human solid tumors.. Cancer Res 1980 Dec;40(12):4438-42.
    pubmed: 7438075
  53. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument.. ANZ J Surg 2003 Sep;73(9):712-6.
    doi: 10.1046/j.1445-2197.2003.02748.xpubmed: 12956787google scholar: lookup
  54. Slovis NM, McEntee MC, Fairley RA, Galuppo LD, Théon AP. Equine basal cell tumors: 6 cases (1985-1999).. J Vet Intern Med 2001 Jan-Feb;15(1):43-6.
    doi: 10.1111/j.1939-1676.2001.tb02296.xpubmed: 11215910google scholar: lookup
  55. Spugnini EP, D’ Alterio GL, Dotsinsky I. Electrochemotherapy for the treatment of multiple melanomas in a horse. J Equine Vet Sci 31:430–433.
    doi: 10.1016/j.jevs.2011.01.009google scholar: lookup
  56. Stewart AA, Rush B, Davis E. The efficacy of intratumoural 5-fluorouracil for the treatment of equine sarcoids.. Aust Vet J 2006 Mar;84(3):101-6.
    doi: 10.1111/j.1751-0813.2006.tb12239.xpubmed: 16555558google scholar: lookup
  57. Szincsák N, Hegyesi H, Hunyadi J, Martin G, Lázár-Molnár E, Kovács P, Rivera E, Falus A, Juhász I. Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line.. Melanoma Res 2002 Jun;12(3):231-40.
    doi: 10.1097/00008390-200206000-00006pubmed: 12140379google scholar: lookup
  58. Teixeira RB, Rendahl AK, Anderson SM, Mickelson JR, Sigler D, Buchanan BR, Coleman RJ, McCue ME. Coat color genotypes and risk and severity of melanoma in gray quarter horses.. J Vet Intern Med 2013 Sep-Oct;27(5):1201-8.
    doi: 10.1111/jvim.12133pubmed: 23875712google scholar: lookup
  59. Théon AP, Pascoe JR, Meagher DM. Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae.. J Am Vet Med Assoc 1994 Oct 15;205(8):1170-6.
    pubmed: 7890578
  60. Théon AP, Pascoe JR, Madigan JE, Carlson G, Metzger L. Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses.. Am J Vet Res 1997 Apr;58(4):431-6.
    pubmed: 9099393
  61. Théon AP. Intralesional and topical chemotherapy and immunotherapy. Vet Clin North Am Equine Pract 14:659–671, viii.
    doi: 10.1016/s0749-0739(17)30191-8google scholar: lookup
  62. Théon AP, Pascoe JR, Galuppo LD, Fisher PE, Griffey SM, Madigan JE. Comparison of perioperative versus postoperative intratumoral administration of cisplatin for treatment of cutaneous sarcoids and squamous cell carcinomas in horses.. J Am Vet Med Assoc 1999 Dec 1;215(11):1655-60.
    pubmed: 14567430
  63. Théon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004).. J Am Vet Med Assoc 2007 May 15;230(10):1506-13.
    doi: 10.2460/javma.230.10.1506pubmed: 17504043google scholar: lookup
  64. Théon AP, Pusterla N, Magdesian KG, Wittenburg L, Marmulak T, Wilson WD. A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor-bearing equidae.. J Vet Intern Med 2013 Nov-Dec;27(6):1581-8.
    doi: 10.1111/jvim.12144pubmed: 24107145google scholar: lookup
  65. Valentine BA. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991).. J Vet Intern Med 1995 Sep-Oct;9(5):291-7.
    doi: 10.1111/j.1939-1676.1995.tb01087.xpubmed: 8531173google scholar: lookup
  66. Valentine BA, Calderwood Mays MB, Cheramie HS. Anaplastic malignant melanoma of the tail in non-grey horses. Equine Vet Educ 26:156–158.
    doi: 10.1111/eve.12105google scholar: lookup
  67. Weber LA, Funtan A, Paschke R, Delarocque J, Kalbitz J, Meißner J, Feige K, Kietzmann M, Cavalleri JV. In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer.. PLoS One 2020;15(11):e0241448.
    doi: 10.1371/journal.pone.0241448pubmed: 33151949pmc: 7643960google scholar: lookup
  68. Weber LA, Puff C, Kalbitz J, Kietzmann M, Feige K, Bosse K, Rohn K, Cavalleri JV. Concentration profiles and safety of topically applied betulinic acid and NVX-207 in eight healthy horses-A randomized, blinded, placebo-controlled, crossover pilot study.. J Vet Pharmacol Ther 2021 Jan;44(1):47-57.
    doi: 10.1111/jvp.12903pubmed: 32845519google scholar: lookup
  69. Weber LA, Delarocque J, Feige K, Kietzmann M, Kalbitz J, Meißner J, Paschke R, Cavalleri JV. Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses.. Animals (Basel) 2021 Nov 13;11(11).
    doi: 10.3390/ani11113250pubmed: 34827981pmc: 8614291google scholar: lookup
  70. Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I, Fullen DR, Joseph N, Bastian BC, Patel RM, Martincorena I, Robles-Espinoza CD, Iyer V, Kuijjer ML, Arends MJ, Brenn T, Harms PW, Wood GA, Adams DJ. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.. Nat Commun 2019 Jan 21;10(1):353.
    doi: 10.1038/s41467-018-08081-1pubmed: 30664638pmc: 6341101google scholar: lookup
  71. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.. J Immunol 1998 Oct 1;161(7):3400-7.
    doi: 10.4049/jimmunol.161.7.3400pubmed: 9759857google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.